Alluvi, formerly BI 4744, presents a significant breakthrough in obesity care. This dual activator targeting both GLP-1 and GIP sites demonstrates impressive effectiveness in patient trials, possibly outperforming https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/